Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 6/20 | 0.75 |
| ▸ | NT5E | P21589 | 1/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.66 |
| ▸ | GSK3A | P49840 | 2/20 | 0.65 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.65 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.65 |
| ▸ | TGM2 | P21980 | 1/20 | 0.64 |
| ▸ | PNP | P00491 | 1/20 | 0.62 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.59 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.58 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.58 |
| ▸ | KRAS | P01116 | 5/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6239924 | 0.92 | HINT1 (0.73) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL18520144 | 0.91 | HINT1 (0.64) | HINT1NT5EADORA3GSK3ARPS6KA3 | |
| SCHEMBL6889003 | 0.91 | HINT1 (0.70) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL2335177 | 0.90 | HINT1 (0.69) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| 2'-Beta-Methyl-Guanosine SCHEMBL11965261 | 0.90 | HINT1 (0.75) | HINT1NT5EADORA3GSK3ARPS6KA3 | |
| 2'-Beta-Methyl-Guanosine SCHEMBL14178410 | 0.90 | HINT1 (0.75) | HINT1NT5EADORA3GSK3ARPS6KA3 | |
| 2'-Beta-Methyl-Guanosine SCHEMBL15338533 | 0.90 | HINT1 (0.75) | HINT1NT5EADORA3GSK3ARPS6KA3 | |
| 2'-Beta-Methyl-Guanosine SCHEMBL383785 | 0.90 | HINT1 (0.75) | HINT1NT5EADORA3GSK3ARPS6KA3 | |
| 2'-Beta-Methyl-Guanosine SCHEMBL116165 | 0.90 | HINT1 (0.75) | HINT1NT5EADORA3GSK3ARPS6KA3 | |
| SCHEMBL10520858 | 0.90 | HINT1 (0.69) | HINT1NT5EGSK3ARPS6KA3MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705468-A1 | MAMMALIAN POLYCISTRONIC EXPRESSION SYSTEM FOR DIRECT TRANSLATION FROM RNA AND SECRETION OF CARGO | California Institute of Technology (US) | 2026-03-11 | — | — | EP | claimed |
| US-12357664-B2 | Optimized oncolytic viruses and uses thereof | SATOR THERAPEUTICS (US) | 2025-07-15 | — | — | US | claimed |
| WO-2025038853-A1 | USHER SYNDROME-RELATED GENE MODIFICATION | AMBER BIO INC. (US) | 2025-02-20 | — | — | WO | claimed |
| WO-2024229296-A1 | MAMMALIAN POLYCISTRONIC EXPRESSION SYSTEM FOR DIRECT TRANSLATION FROM RNA AND SECRETION OF CARGO | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2024-11-07 | — | — | WO | claimed |
| EP-4244356-A1 | CHEMICAL MODIFICATIONS FOR INHIBITING EXPRESSION OF ALDH2 | Dicerna Pharmaceuticals, Inc. (US) | 2023-09-20 | — | — | EP | claimed |
| WO-2022104366-A1 | CHEMICAL MODIFICATIONS FOR INHIBITING EXPRESSION OF ALDH2 | DICERNA PHARMACEUTICALS, INC. (US) | 2022-05-19 | — | — | WO | claimed |
| US-20220088097-A1 | OPTIMIZED ONCOLYTIC VIRUSES AND USES THEREOF | SATOR THERAPEUTICS | 2022-03-24 | — | — | US | claimed |
| EP-0948256-A4 | INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA | UNIV WASHINGTON (US) | 2007-10-24 | — | — | EP | claimed |
| US-6887707-B2 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | UNIVERSITY OF WASHINGTON (US) | 2005-05-03 | — | — | US | claimed |
| US-20030119764-A1 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-06-26 | — | — | US | claimed |
| EP-0948256-A1 | INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA | THE UNIVERSITY OF WASHINGTON (US) | 1999-10-13 | — | — | EP | claimed |
| WO-1998018324-A1 | INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA | THE UNIVERSITY OF WASHINGTON (US) | 1998-05-07 | — | — | WO | claimed |
| WO-2026102473-A1 | TEMPERATURE DEPENDENT PROBES FOR TARGET DETECTION | SPEEDX PTY LTD (AU) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026104647-A1 | VACCINE | ASTRAZENECA AB (SE) | 2026-05-21 | — | — | WO | disclosed |
| EP-4739794-A1 | METHODS, COMPOSITONS, AND SYSTEMS FOR ANALYTE DETECTION | Stellaromics, Inc. (US) | 2026-05-13 | — | — | EP | disclosed |
| EP-4735035-A2 | SARS-COV-2 RNA VACCINES AND USES THEREOF | Seqirus Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20030119764-A1 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-06-26 | — | — | US | disclosed |
| WO-2003039450-A2 | IMPROVEMENTS IN OR RELATING TO INHIBITION OF VIRUSES | MEDICAL RESEARCH COUNCIL (GB) | 2003-05-15 | — | — | WO | disclosed |
| EP-0948256-A1 | INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA | THE UNIVERSITY OF WASHINGTON (US) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998018324-A1 | INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA | THE UNIVERSITY OF WASHINGTON (US) | 1998-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119764-A1 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | SAMHD1, BCDIN3D, DCTD | HINT1 280/4885NT5E 846/4885ADORA3 1762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.